Ogivri

Active Ingredient(s): Trastuzumab-dkst
FDA Approved: * December 1, 2017
Pharm Company: * MYLAN GMBH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ogivri Overview

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.[3][4][5][6] It is specifically used for cancer that is HER2 receptor positive.[3] It may be used by itself or together with other chemotherapy medication.[3] Trastuzumab is given by slow injection into a vein and injection just under the skin.[3]&am...

Read more Ogivri Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Trastuzumab

Recent Ogivri Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Trastuzumab-dkst
  • Injection: 100mg, 150mg, 420mg, 420mg/vial, 440mg, 600mg + 10000units
  • Vial: 100mg, 150mg, 160mg, 21mg/ml, 420mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ogivri: (3 results)

Sorted by National Drug Code
  • 67457-845 Ogivri 420 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution by Mylan Institutional LLC
  • 67457-847 OgivriOgivri Kit by Mylan Institutional LLC
  • 67457-991 Ogivri 150 mg/7.4ml Intravenous Injection, Powder, Lyophilized, for Solution by Mylan Institutional LLC

Other drugs which contain Trastuzumab-dkst or a similar ingredient: (12 results)